长春瑞滨联合铂类治疗中晚期子宫内膜癌

Clinical study of vinorelbine plus cisplatin for patients with advanced or recurrent endometrial carcinoma

目的:比较长春瑞滨和紫杉醇分别与铂类联合治疗中晚期子宫内膜癌的近期疗效及毒副反应。方法:33例晚期子宫内膜癌,治疗组(NP方案组)21例,长春瑞滨+顺铂或卡铂化疗,长春瑞滨25mg/m2,静注d1、8;顺铂25mg/m2,静注d1～3,或卡铂(300mg/m2或者AUC4～5)静脉滴注d1。对照组(TP方案组)12例:紫杉醇135～150mg/m2,静注d1;顺铂或卡铂用法同前。结果:全组均完成2周期以上化疗,其中CR4例,PR14例,NC10例,PD5例。有效率(CR+PR)54.54%。NP方案组,CR2例,PR9例,有效率(CR+PR)52.38%;TP方案组,CR2例,PR5例,有效率(CR+PR)58.33%,两组间无统计学差异(P(0.05)。副反应主要为骨髓抑制、白细胞、血小板减少,Ⅲ～Ⅳ度发生率,NP组为71.43%,TP组为75.0%(P(0.05)。结论:长春瑞滨+铂类联合与紫杉醇+铂类联合化疗治疗中晚期子宫内膜癌有相同的疗效且毒副反应可以耐受。

Objective： To compare the difference between vinorelbine plus cisplatin and paclitaxel plus cisplatin in clinical effect and side effect in treatment of advanced or recurrent endometrial carcinoma. Methods：Thirty three patients with advanced or recurrent endometrial carcinoma were enrolled into two groups, 21 cases in group NP, vinorelbine was given by 25mg/m^2 iv drop d1,8, cisplatin 25mg/m^2 iv drop d1- 3 ; 12 cases in group TP, paclitaxel 135mg/m^2 or 150mg/m^2,iv drop dl, cisplatin 25mg/m^2 iv drop d1- 3. Results：Out of 33 evaluable patients,4 patients were in CR, 14 were in PR,the effective rate （CR ＋ PR） was 52.38% ; 21 and 12 patients respectively in group NP and TP could be evaluated, RR （CR ＋ PR） were 52.38% and 58.33%. Conclusion： The combination chemotherapy with vinorelbine plus cisplatin in treatment of advanced or recurrent endometrial carcinoma is effective and the side effects could be tolerated.